利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.053 秒)

    Glucopyranoside compound
    4.
    发明授权
    Glucopyranoside compound 有权
    吡喃葡萄糖苷化合物

    公开(公告)号：US07943788B2

    公开(公告)日：2011-05-17

    申请号：US11045446

    申请日：2005-01-31

    申请人： Sumihiro Nomura ,  Eiji Kawanishi ,  Kiichiro Ueta

    发明人： Sumihiro Nomura ,  Eiji Kawanishi ,  Kiichiro Ueta

    IPC分类号： C07D409/00 ,  A01N43/04 ,  C07D277/04 ,  C07D277/08 ,  C07D487/00 ,  C07D257/04 ,  C07D257/10 ,  C07D403/00

    CPC分类号： C07H19/048 ,  A61K45/06 ,  C07D405/04 ,  C07D409/04 ,  C07D409/10 ,  C07H19/06

    摘要： A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译： 下式的化合物：其中环A和环B是：（1）环A是任选取代的不饱和单环杂环，环B是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环，或 任选取代的苯环，（2）环A是任选取代的苯环，环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环，或（3）环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - （CH 2）n - （n为1或2）; 其药学上可接受的盐或其前药。

    Indole derivatives
    5.
    发明授权
    Indole derivatives 有权
    吲哚衍生物

    公开(公告)号：US07851617B2

    公开(公告)日：2010-12-14

    申请号：US11878760

    申请日：2007-07-26

    申请人： Sumihiro Nomura ,  Shigeki Sakamaki

    发明人： Sumihiro Nomura ,  Shigeki Sakamaki

    IPC分类号： C07H19/044 ,  C07H19/056 ,  A01N43/04 ,  A61K31/70

    CPC分类号： C07H19/04

    摘要： Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is fluorine, or chlorine, and R2 is hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.

    摘要翻译： 式（I）的新型吲哚衍生物或其药学上可接受的盐：其中R1是氟或氯，R2是氢或氟，它们是SGLT抑制剂，并且可用于治疗或预防糖尿病和相关病症。

    Novel compounds
    7.
    发明申请
    Novel compounds 有权
    新型化合物

    公开(公告)号：US20050233988A1

    公开(公告)日：2005-10-20

    申请号：US11045446

    申请日：2005-01-31

    申请人： Sumihiro Nomura ,  Eiji Kawanishi ,  Kiichiro Ueta

    发明人： Sumihiro Nomura ,  Eiji Kawanishi ,  Kiichiro Ueta

    IPC分类号： A61K31/7072 ,  C07H19/048 ,  C07H19/06

    CPC分类号： C07H19/048 ,  A61K45/06 ,  C07D405/04 ,  C07D409/04 ,  C07D409/10 ,  C07H19/06

    摘要： A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译： 下式的化合物：其中环A和环B是：（1）环A是任选取代的不饱和单环杂环，环B是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环，或 任选取代的苯环，（2）环A是任选取代的苯环，环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环，或（3）环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y是 - （CH 2）n - （n是1或2）; 其药学上可接受的盐或其前药。

    S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
    8.
    发明授权
    S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof 失效
    S型2-取代羟基-2-吲哚哩啶基丁酸酯化合物及其制备方法

    公开(公告)号：US06716983B2

    公开(公告)日：2004-04-06

    申请号：US10337476

    申请日：2003-01-08

    申请人： Takayuki Kawaguchi ,  Sumihiro Nomura ,  Kenji Tsujihara

    发明人： Takayuki Kawaguchi ,  Sumihiro Nomura ,  Kenji Tsujihara

    IPC分类号： C07D49120

    CPC分类号： C07D491/14 ,  C07B2200/07 ,  C07D209/42 ,  C07D217/26

    摘要： A process for preparing S type 2-substituted hydroxy-2-indolidinylbutyric ester compound [II]: wherein Ro is residue of nitrogen-containing fused heterocyclic carboxylic acid having absolute configuration of “R” (in which the nitrogen atom is protected), R1 and R2 are lower alkyl groups, and E is ester residue, which is useful as an intermediate for preparing camptothecin derivatives having antitumor activities, which comprises 2-ethylating 2-substituted hydroxy-2-indolidinylacetic ester compound [I]: wherein the symbols are as defined above.

    摘要翻译： 制备S型2-取代羟基-2-吲哚哩啶基丁酸酯化合物[II]的方法：其中R 0是具有绝对构型“R”（其中氮原子被保护的）的含氮稠合杂环羧酸的残基 ），R1和R2是低级烷基，E是酯残基，其可用作制备具有抗肿瘤活性的喜树碱衍生物的中间体，其包括2-乙基化2-取代的羟基-2-吲哚哩啶基乙酸酯化合物[I]：其中 符号如上所述。